Ionis Pharmaceuticals Inc (IONS) : Capital Counselny scooped up 10,100 additional shares in Ionis Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 28,530 shares of Ionis Pharmaceuticals Inc which is valued at $999,406.Ionis Pharmaceuticals Inc makes up approximately 0.09% of Capital Counselny’s portfolio.
Other Hedge Funds, Including , Tower Research Capital (trc) boosted its stake in IONS in the latest quarter, The investment management firm added 809 additional shares and now holds a total of 850 shares of Ionis Pharmaceuticals Inc which is valued at $29,776.Teacher Retirement System Of Texas boosted its stake in IONS in the latest quarter, The investment management firm added 2,036 additional shares and now holds a total of 8,577 shares of Ionis Pharmaceuticals Inc which is valued at $308,000. Brown Advisory Inc sold out all of its stake in IONS during the most recent quarter. The investment firm sold 5,369 shares of IONS which is valued $192,801. Global X Management Co added IONS to its portfolio by purchasing 262 company shares during the most recent quarter which is valued at $9,406.
On the company’s financial health, Ionis Pharmaceuticals Inc reported $-0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.50. The company had revenue of $38.50 million for the quarter, compared to analysts expectations of $38.45 million. The company’s revenue was down -68.0 % compared to the same quarter last year.
Many Wall Street Analysts have commented on Ionis Pharmaceuticals Inc. Company shares were Reiterated by Piper Jaffray on Aug 10, 2016 to “Overweight”, Firm has raised the Price Target to $ 46 from a previous price target of $36 .Morgan Stanley Initiated Ionis Pharmaceuticals Inc on Aug 3, 2016 to “Equal-Weight”, Price Target of the shares are set at $37.Company shares were Reiterated by Needham on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 64 from a previous price target of $55 .
Ionis Pharmaceuticals Inc. formerly Isis Pharmaceuticals Inc. is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases including cardiovascular; metabolic; severe and rare diseases including neurological disorders and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs nusinersen volanesorsen and IONIS-TTR to the market. Its lipid-lowering product KYNAMRO (mipomersen sodium) injection is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen IONIS-DMPK-2.5 Plazomicin and IONIS-GCGR.